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Abstract: Large genomic rearrangements (LGRs) affecting one or more exons of BRCA1 and BRCA2
constitute a significant part of the mutation spectrum of these genes. Since 2004, the National Institute
of Oncology, Hungary, has been involved in screening for LGRs of breast or ovarian cancer families
enrolled for genetic testing. LGRs were detected by multiplex ligation probe amplification method,
or next-generation sequencing. Where it was possible, transcript-level characterization of LGRs was
performed. Phenotype data were collected and analyzed too. Altogether 28 different types of LGRs in
51 probands were detected. Sixteen LGRs were novel. Forty-nine cases were deletions or duplications
in BRCA1 and two affected BRCA2. Rearrangements accounted for 10% of the BRCA1 mutations.
Three exon copy gains, two complex rearrangements, and 23 exon losses were characterized by exact
breakpoint determinations. The inferred mechanisms for LGR formation were mainly end-joining
repairs utilizing short direct homologies. Comparing phenotype features of the LGR-carriers to that
of the non-LGR BRCA1 mutation carriers, revealed no significant differences. Our study is the largest
comprehensive report of LGRs of BRCA1/2 in familial breast and ovarian cancer patients in the Middle
and Eastern European region. Our data add novel insights to genetic interpretation associated to
the LGRs.
Keywords: BRCA1; BRCA2; large genomic rearrangement; familial breast cancer; copy number
analysis; breakpoint characterization; deletion; duplication
1. Introduction
Germline pathogenic single nucleotide variations (SNVs) and small indels of the BRCA1 and
BRCA2 genes are well-studied genetic changes in hereditary breast and ovarian cancers [1]. However,
large genomic rearrangements (LGRs), including deletions and duplications affecting whole exons also
contribute to the mutational landscape of these genes. Surveys from different populations documented
that approximately 10% of the overall BRCA1/2 germline mutations are LGRs, but the exact ratios are
strongly population dependent. LGRs in BRCA1 are responsible for between 0% and 27% of all BRCA1
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disease-causing mutations identified in numerous populations. Such alterations are far less common
in the BRCA2 gene [2–17]. These chromosomal changes are not readily detectable by conventional
sequencing, but require copy-number sensitive methods, such as multiplex ligation-dependent probe
amplification (MLPA) [18], quantitative multiplex PCR of short fluorescent fragments (QMPSF) [19],
or comparing the relative numbers of the aligned reads yielded by next-generation sequencing
(NGS) [20].
The source of LGRs in the BRCA1/2 genes is mainly recombination between low-copy paralogue
sequences, such as Alu motifs residing in introns [21]. BRCA1, with its markedly Alu-dense
genomic context is especially prone to non-recurrent rearrangements of unique sizes [22]. Although
most LGRs are definitively pathogenic, causing frameshifts and premature termination codons,
some rearrangements have ambiguous effects, especially in-frame deletions of redundant exons [23] or
some duplications, where additional copies of exons might be tolerated [7] or may as well be posited
in a different genomic context.
From 2004, the Department of Genetics of National Institute of Oncology, Budapest, Hungary,
has been involved in the BRCA1/2 germline mutation screening of the enrolled high-risk Hungarian
breast and ovarian cancer patients. We performed a comprehensive characterization of LGRs detected
in our patients. Exact determination of their position, frequency, and pathogenicity were studied and
we also made attempts to decipher the underlying molecular mechanisms of each LGR. Transcript-level
evaluations of the variants were done in cases, where RNA samples of the probands could be obtained:
this approach provided precious information concerning splicing consequences and allelic expressions.
We also analyzed phenotype features observed in families harboring LGRs in order to test whether
LGRs confer more severe disease than other small-scale mutations of the gene.
Our study is the first comprehensive report of LGRs of BRCA1 and BRCA2 genes in Hungarian
familial breast and ovarian cancer patients and the largest survey in the Middle and Eastern
European region.
2. Results
As part of the routine genetic testing in our department we screened for LGRs affecting whole
exons of the BRCA1/2 genes by MLPA as well as by NGS methods. From 2004, we identified altogether
51 LGRs in index patients of unrelated breast or ovarian cancer families (Table 1, Table S2). An example
for BRCA1 del(ex18–22) detection by NGS is shown in Figure S1. Of the detected LGRs 49 were variants
of BRCA1 and only two affected BRCA2. LGRs of BRCA1 accounted for approximately 10% of the
overall BRCA1 mutations, whereas BRCA2 LGRs took up ≤0.5% of the total BRCA2 mutations.
With the application of serial long-range PCRs and nested sequencings of the breakpoint-containing
PCR products (the junction fragments) we determined the exact upstream (5’) and downstream (3’)
breakpoints of each rearrangement, where it was feasible. Breakpoint determination with the examples
of BRCA1 del(ex24), BRCA1 del (ex1-20), and BRCA1 del(ex8) rearrangements are depicted in Figure 1.
Junction position sequencing of all novel LGRs are presented in Figure S2. In all but four cases we
managed to determine the exact breakpoints of LGRs. In the remaining cases the breakpoints were
also successfully restricted to a more limited interval with semi-quantitative tests. With the help of
real-time qPCR and QMPSF tests we pointed out the positions of the actual breakpoints with some
hundred base pairs certainty (Figure 2A,B).
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3 BRCA1 BRCA1dup(ex1-2) dup NG_005905.2:g.90060_97318dup NA NA [7] AluY AluYk4 48 bp NAHR




(AluSp) 15 bp NAHR
1 BRCA1 BRCA1del(ex1-2) del NG_005905.2:g.59885_96193del NA NA NA PsiBRCA1 BRCA1 intron 2 62 bp NAHR
1 BRCA1 BRCA1del(ex1-3) del NG_005905.2:g.(24943_26402)_(102259_111450)del NA NA NA NA NA NA NA
1 BRCA1 BRCA1del(ex1-3) del NG_005905.2:g.(88971_92304)_(102259_111450)del NA NA NA NA NA NA NA
1 BRCA1 BRCA1del(ex1-3) del NG_005905.2:g.84958_106171del NA NA NA AluY AluY 4 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex1-20) del NG_005905.2:g.33502_166230del NA NA NA AluSx AluSg 27 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex3-13) del LRG_292t1:c.(81-2037_81-1)_(4357+1_4358-1)del NA NA NA NA NA NA NA
1 BRCA1 BRCA1del(ex5) del LRG_292t1:c.135-30_212+136del NA NA [8] Non-Alu Non-Alu 9 bp NHEJ
1 BRCA1 BRCA1del(ex5-7) del LRG_292t1:c.135-1004_441+1608del NA NA [8] AluSz6 AluSc5 15 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex5-10) del LRG_292t1:c.135-4505_670+361delins35 LRG_292t1:r.135_670del p.(Lys45AsnfsTer3) [3] AluSx/AluY AluY/AluJb 10 bp/29 bp FoSTeS
2 BRCA1 BRCA1del(ex8) del LRG_292t1:c.441+1521_547+392del LRG_292t1:r.442_547del p.(Gln148AspfsTer50) NA AluSc5 AluSp 13 bp MMEJ/SSA
2 BRCA1 BRCA1del(ex8) del LRG_292t1:c.442-1102_547+252del NA NA [24] AluSx AluSp 26 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex8) del LRG_292t1:c.442-1830_547+295del NA NA NA AluSz AluSp 11 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex11a) del LRG_292t1:c.671-216_901del NA NA NA non-Alu non-Alu 4 bp NHEJ
1 BRCA1 BRCA1del(ex11b-12) del LRG_292t1:c.1644_4185+3618del NA NA [25] non-Alu L1 3 bp NHEJ
8 BRCA1 BRCA1dup(ex13) dup LRG_292t1:c.4186-1787_4357+4122dup NA NA [26] AluSx AluSx1 23 bp unknown
1 BRCA1 BRCA1del(ex14) del LRG_292t1:c.4357+1661_4485-338del NA NA NA AluJo AluSx1 10 bp MMEJ/SSA
4 BRCA1 BRCA1del(ex17) del LRG_292t1:c.4986+726_5074+84del LRG_292t1:r.4987_5074del p.(Val1665SerfsTer7) [27,28] AluSp AluSc 10 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex17-19) del LRG_292t1:c.4987-365_5194-484del NA NA [29] AluY AluY 43 bp MMEJ/SSA













1 BRCA1 BRCA1del(ex20) del LRG_292t1:c.5213_5278-2753delinsA † NA NA [30] non-Alu AluSp no NHEJ
2 BRCA1 BRCA1del(ex18-22) del LRG_292t1:c.5075-1135_5406+346del LRG_292t1:r.5075_5406del p.(Asp1692GlyfsTer26) [3] AluY AluSz 7 bp MMEJ/SSA
9 BRCA1 BRCA1del(ex21-22) del LRG_292t1:c.5278-492_5407-128delins236 LRG_292t1:r.5278_5406del p.(Ile1760_Thr1802) [25] non-Alu/AluSx AluSx/AluJb 26 bp FoSTeS
1 BRCA1 BRCA1del(ex21-22) del LRG_292t1:c.5277+2114_5407-689del LRG_292t1:r.5278_5406del p.(Ile1760_Thr1802) NA AluSq2 AluSc 8 bp MMEJ/SSA
1 BRCA1 BRCA1del(ex24) del LRG_292t1:c.5506_*1383+36del NA NA NA non-Alu non-Alu 4 bp NHEJ
1 BRCA1 BRCA1del(ex24) del LRG_292t1:c.5468-364_*749del NA NA NA AluSx AluSx1 45 bp MMEJ/SSA
1 BRCA2 BRCA2del(ex11a) del LRG_293t1:c.1910-92_3888del NA NA NA non-Alu non-Alu no NHEJ
1 BRCA2 BRCA2amp(ex21) amp LRG_293t1:c.(8633-70_8633-1)_ (8754+78_8754+122)ampNA NA NA NA NA NA unknown
Designations of the LGRs are according to the current HGVS (Human Genome Variation Society) nomenclature. † This variant was described by Belogianni et al., 2004 [30], with the
exception that we found an additional adenine residue inserted at the junction position. A shorter running name is given for rearrangement types for easier reference in the text. Novel LGRs,
reported first in this article are highlighted with bold. Reference is given for formerly described LGRs. RNA nomenclature and inferred protein effects are determined, where cDNA-level
sequencing was performed. NAHR: non-allelic homologues recombination, NHEJ: non-homologues end-joining, MMEJ/SSA: microhomology-mediated end-joining/single-strand
annealing, FoSTeS: fork stalling and template switching.
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Figure 1. Representative examples of breakpoint determination in three rearrangement types. A: BRCA1 
del(ex24) samples, B: BRCA1 del(ex1-20) sample, and C: BRCA1 del(ex8) samples. Upper panels: agarose gel 
visualization of the junction fragments. Lower panels: breakpoint spanning sequence electropherograms of 
the junction fragments. L: Hyper Ladder 1 kb DNA sizing standard. C1 and C2 are BRCA1/2 negative control 
samples. Red bars represent the concerted breakpoints according to the 3’ rule. Yellow boxes highlight the 
perfect sequence homologies at the breakpoint junctions. Exact base sequences surrounding the breakpoints 
Figure 1. Representative examples of breakpoint determination in three rearrangement types.
(A): BRCA1 del(ex24) samples, (B): BRCA1 del(ex1-20) sample, and (C): BRCA1 del(ex8) samples.
Upper p nels: agarose gel visualizati n of the juncti fr gments. Low r panels: breakpoint
spanning sequence electropherograms of the junction fragments. L: Hyper Ladder 1 kb DNA sizing
standard. C1 and C2 are BRCA1/2 negative control samples. Red bars represent the concerted
breakpoints according to the 3’ rule. Yellow boxes highlight the perfect sequence homologies at
the breakpoint junctions. Exact base sequences surrounding the breakpoints relative to the reference
sequence are shown below the electropherograms. (A): F-1476 is a LRG_292t1:c.5468-364_*749del
heterozygote sample with 1.1 kb deletion and EF-142 is a LRG_292t1:c.5506_*1383+36del heterozygote
sample with 1.5 kb deletion. (B): F-1052 is a NG_005905.2:g.33502_166230del heterozygote sample
with 133 kb deletion. The C1 and C1 samples did not yield PCR product of 136 kb. (C): Sz-2486
is a LRG_292t1:c.441+1521_547+392del heterozygote sample with 3.2 kb deletion and Sz-2557 is
a LRG_292t1:c.442-1830_547+295del heterozygote sample with 2.2 kb deletion. The wild type alleles of
the mutation carrier samples did not yield amplification products.
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Figure 2. Narrowing down the breakpoint intervals with relative quantitation assays. Representative 
examples. A: Quantitative multiplex PCR of short fluorescent fragments (QMPSF) assay of the BRCA1 
del(ex1-3) sample with variant NG_005905.2:g.(88971_92304)_(102259_111450)del (blue) vs. control sample 
(red). R sign denotes amplicon peaks for biallelic control positions, D sign denotes amplicon peaks for 
monoallelic control positions. Q1 and Q2 denote queried positions of the upstream breakpoint interval, 
which was formerly confined to this region by multiplex ligation-dependent probe amplification (MLPA). 
Both query positions were biallelic, thus deletion breakpoint should be downstream of these positions. The 
inferred breakpoint interval is highlighted with brace on the graphic of the tested chromosomal region 
beneath the electropherogram. Red bars are exons for BRCA1, green bars are exons for NBR2. B: Real-time 
qPCR result for BRCA1 del(ex24) samples with variants LRG_292t1:c.5468-364_*749del (F-1476) and 
Figure 2. Narrowing down the breakpoint intervals with relative quantitation assays. Representative
examples. (A): Quantitative multiplex PCR of short fluorescent frag ents (Q PSF) assay of the BRCA1
del(ex1-3) sample with variant NG_005905.2: 971_92304)_(102259_111450)del (blue) vs. control
sample (re ). sign denotes amplicon peaks for biallelic control positio s, D sign denotes amplicon
peaks for monoallelic control positions. Q1 and Q2 denote queried positions of the upstream
breakpoint interval, which was formerly confined to this region by multiplex ligation-dependent
probe amplification (MLPA). Both query positions were biallelic, thus deletion breakpoint should be
downstream of th s positi ns. The inferred breakpoint interval is highlighted with brace on the
graphic of the tested chromosomal region beneath the electropherogram. Red bars are exons for
BRCA1, green bars are exons for NBR2. (B): Real-time qPCR result for BRCA1 del(ex24) samples with
variants LRG_292t1:c.5468-364_*749del (F-1476) and LRG_292t1:c.5506_*1383+36del (EF-142). Four bars
per amplicon represent the ∆∆Ct values of each BRCA1 del(ex24) samples relative to two different
calibrators (C1 and C2). The standard errors of technical triplicates were below 5% for all measurements,
so error bars are not shown. Position and numberings of the designed amplicon targets from BRCA1
exon 24 towards downstream region of the gene is depicted on the graphic of the tested chromosomal
interval beneath the chart. Red bars are exons for BRCA1, magenta bars are exons for RND2. Only the
amplicon designed for BRCA1 exon 24 showed deletion in both families, thus downstream deletion
interval is restricted to the region between amplicons 1 and 2 (showed within brace).
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Breakpoint characterization unveiled that the 51 unrelated cases made up from 26 different
rearrangements (24 deletions and two duplications) in theBRCA1gene and two different rearrangements
(one deletion and one multiplication) in the BRCA2 gene (Figure 3, Table 1). Of the 28 different
rearrangements, 24 were successfully genotyped for the exact upstream and downstream break
positions. Seventeen of them (70.8%) had Alu sequences at both 5’ and 3’ breakpoints. Moreover,
six of them had both breakpoints in the same Alu family (AluY-AluY, AluSx-AluSx), that provided
even larger sequence homeology. In all cases Alus were in the same orientation for both breakpoints
(14 times head-to tail, three times tail-to-head relative to the gene transcript orientation). The average
size of the complete homology was 19 bp at the junctions. In six cases we experienced no homeology,
and limited or no sequence homology at the breakpoint positions. Two different rearrangements
contained short reverse complement insertions beside deletions (complex rearrangements).
LGRs spanned all regions of BRCA1 gene, no regional hot spots were detected, except for
BRCA1 pseudogene region, which is especially prone for rearrangements. The exact positions
of breakpoints inside Alus were also spread evenly throughout the whole Alu region; no seed
sequence dedicated for the rearrangements was identified. Interestingly, a BRCA1 del(ex1-2) variant
NG_005905.2:g.59989_96300del had junction point especially inside the polyA tail. The size of deletions
ranged from 450 base pairs to several tens of kilobases. In total, seven different rearrangements, where
deletion or duplication extended upstream the BRCA1 gene and also affected the promoter region,
were identified.
There were some recurrent LGRs with the same genomic breakpoints: BRCA1 dup(ex13)
LRG_292t:c.4186-1787_4357+4122dup was found in eight families, whereas BRCA1 dup(ex1-2)
NG_005905.2:g.90060_97318dup was detected in three index patients of different families. BRCA1 del(ex17)
LRG_292t1:c.4986+726_5074+84del and BRCA1 del(ex21-22) LRG_292t1:c.5278-492_5407-128delins236
were detected in four and nine families, respectively.
We contrasted personal and family history as well as some clinical variables of LGR-carriers
to those of non-LGR pathogenic BRCA1 variant carriers. For this latter group we used a cohort of
281 well-characterized samples with non-LGR pathogenic and likely pathogenic mutations identified
through routine clinical diagnostic testing. The phenotype features of the LGR-carrier probands and
their families are detailed in Table S3. Neither the personal of familial phenotypes nor the clinical
variables showed any significant difference between the LGR and the non-LGR BRCA1 mutation
carriers (Table S3). Six families, where deletion stretched further upstream the BRCA1 gene affecting
also the BRCA1 and NBR2 common promoter or even the NBR2 of NBR1 genes themselves did not
show more severe disease pathology than LGRs restricted to the BRCA1 open reading frame. However,
this lack of genotype–phenotype correlation might be the consequence of the small number of cases
carrying such rearrangements.
Haplotyping of three recurrent rearrangements, BRCA1 del(ex17), BRCA1 del(ex21-22), and BRCA1
dup(ex13) was done with the help of polymorphic STR markers inside and surrounding the BRCA1
gene recommended by Neuhausen et al. (1996) [31], as well as with SNPs inside the BRCA1 gene,
where it was applicable. All three LGR types, where breakpoint chromosomal positions were the same,
proved to be of the same origin according to the genotypes of the respective core haplotypes (Table S4).
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Figure 3. Position of the detected large genomic rearrangements (LGRs) along the BRCA1 and BRCA2 genes. Genes are drawn in sense orientation without promoter
region. The length of exons (black bars) and introns (grey bars) are not exactly to scale. Exon numberings are given above them. Each different LGR variant is
represented once. Deletions are depicted with grey boxes, duplications are depicted with striped boxes. Respective LGR running names indicating their exon affections
are listed on the left. Arrows indicate that the rearrangements outreached the gene towards upstream direction. LGRs with uncertain breakpoints are labeled with
an asterisk. Additionally, where breakpoint uncertainty is larger than 1 kb, dashed outlines of the bars indicate the possible breakpoint intervals.
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Transcript-level examination of the variant allele was possible in eight families of six different
LGRs (see RNA column of Table 1). These involved BRCA1 del(ex21-22) variants with two different
breakpoint positions. PCR on the cDNA templates with primers surrounding the deleted exons yielded
shorter extra products in each case, reflecting the successful amplification also from the mutant allele
(Figure 4A,B). Sequencing these fragments pointed out that only the deletion-affected exons were
missing in all tested LGR types, so exon deletion on gDNA level reflected exactly on RNA level in
each case, the function of the neighboring canonical exon splicing positions were not affected. In order
to evaluate the relative expression quantity of the two alleles, we performed an allelic imbalance
test, where heterozygote positions made it feasible. The ratio of the deletion carrier allele was much
less (≤50%) than the normal allele in two deletion types: BRCA1 del(ex5-10) and BRCA1 del(ex17)
(Figure 4A), but equivalent expression of the two alleles was experienced in BRCA1 del(ex21-22)
(Figure 4B) and BRCA1 del(ex18-22).
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 Figure 4. RT-PCR product, cDNA-level sequencing and allele expression ratio of (A): BRCA1
del(ex17) and (B): BRCA1 del(ex21-22) samples. PCR amplifications were done on cDNA
templates with cDNA primers locating in exons flanking the rearrangements. Shorter fragments
amplified from the deletion-carrier alleles were obtained in each case (upper boxes, agarose gel
electrophoreses). Sz-2871 is a LRG_292t1:c.4986+726_5074+84del heterozygote variant carrier. F-823 is
a LRG_292t1:c.5277+2114_5407-689del heterozygote variant carrier and F-794, F-96, Sz-677 samples
are LRG_292t1:c.5278-492_5407-128delins236 heterozygote variant carriers. C1–C3: control wild type
samples. Sequencing of the amplified regions resulted in canonical cassette exon junctions flanking
the deleted regions in each family (Sanger sequence electropherograms in the middle boxes show
the superposition of signals of the normal and deleted alleles from the position of the canonical exon
borders). All BRCA1 del(ex21-22) samples yielded the same sequencing result, Sz-677 (underlined)
was represented as an example. Allelic ratio for elected exonic heterozygote positions (c.3548A>G
and c.2082C>T, respectively, indicated by red arrows) were compared to that of the gDNA sequence
according to the electropherogram AUCs (area under the curve) of the nucleotide superpositions
(lower boxes). (A): BRCA1 del(ex17) showed lower amount of transcript from the deleted allele.
(B): BRCA1 del(ex21-22) did not show cDNA allelic ratio difference relative to that the gDNA.
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3. Discussion
In the course of the routine BRCA1/2 testing of our department from the year of 2004, we detected
28 different, 16 novel large genomic rearrangements in 51 probands of unrelated breast or ovarian
families. According to the statistics based on NGS data of our laboratory, BRCA1 LGRs take up
approx. 10% of the overall BRCA1 mutations in Hungary. These frequencies are comparable with
those detected in other Middle European populations [3,4,8], but fall short of the extreme ratios found
in the Netherlands (36% of all BRCA1 mutants) [15], Italy (19% of all BRCA1 mutants) [16], and UK
(20% of all BRCA1 mutants) [5], where frequently occurring founder mutations constitute the majority
of LGR cases.
The bulk of the rearrangements affected the BRCA1 gene, BRCA2 was nearly exempt from LGRs.
This is in concert with the findings worldwide (BRCA1 LGR ratios ranges from 0% to 36%, whereas
BRCA2 LGRs constitute 0–6% of all BRCA mutations [2–17]). The difference is at least partly explained
by the larger number of Alus and other repetitive sequences as well as the pseudogene counterpart
in BRCA1 [32]. Theoretically, the relatively low LGR frequency in BRCA2 might be a consequence
of a biased BRCA2 mutation spectrum due to an over-representation of founder point mutations.
However, but the three most frequent point mutations (c.9097dup; c.5946del, c.7913_7917del) represent
only 26% of all BRCA2 mutations in Hungary, which is very close the respective ratios of the countries
in our region (e.g., Austria: 23%, Czech Republic: 26%, Poland: 26%). Additionally, the three most
frequent founder mutations of BRCA1 (c.5266dup, c.181T>G, and c.68_69del) account for a much
higher ratio (68%) of all BRCA1 pathogenic variants in our population [17,33], but the ratio of LGRs in
BRCA1 is still higher than in BRCA2.
Exact breakpoint characterizations yielded 28 different types of rearrangements. Twelve LGRs
with the same breakpoints have been already reported (see Reference column in Table 1). The remaining
16 types of rearrangements have not been described so far, they may be characteristic to the
Hungarian population.
There were four rearrangement types (two deletions and two duplications) that occurred
recurrently. Neither of them was Hungarian founder mutation, all of them were reported with
similar frequencies in other populations (see Table 1 Reference column), with the exception of BRCA1
del(ex17) LRG_292t1:c.4986+726_5074+84del, which was detected in only one case of 1506 families in
Germany [27]. Noteworthy, neither of the two BRCA1 del(ex1-2) rearrangements was identical with
the reported ones, which underpinned that psiBRCA1 serves as hot spot for recombination.
Among the detected genomic rearrangements deletions prevailed over duplications. This might
indicate that the underlying molecular mechanisms are mainly intrachromatidal events between
repetitive sequences of the same orientation, which are the main source of copy number loss [34].
The exact breakpoint detections enabled us to make suggestions for the mechanisms that are responsible
for the generation of the respective rearrangements. The majority of deletions detected were flanked
by Alu sequences sharing ≈300 bp sequence similarity. This deletion type is used to be attributed
to homologues recombination repair between ectopic sequences, called non-allelic homologues
recombination (NAHR) [21], but novel findings argue that HR events require more extensive homology,
than the typical 300 bp of Alu sequences [35]. Over the past decade, microhomology-mediated end
joining (MMEJ) and single-strand annealing (SSA) mechanisms were suggested for these deletion
types, which are special forms of end joining repair rather than real homologues recombination [36–38].
These mechanisms benefit the extensive homeology between two Alu sequences but actually apply only
a small uninterrupted homology of 5–50 base pairs [37]. We found six LGR types, where no, or very
limited sequence homology was found at the junctions: they may be explained by non-homologues end
joining (NHEJ) [39,40]. Two LGR types with complex rearrangements found in our study (deletions
combined with reverse insertions) may have arisen from the fork stalling and template switching
(FoSTeS) mechanism [41], where the polymerase enzyme stops at defined positions, switches strand to
the opposite direction and resumes back after some hundreds of base pairs of reverse strand elongation.
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The exact nucleotide positions of the upstream and downstream breakpoints are so characteristic,
that they provide sufficient evidence for common origin of the LGRs with the same breakpoints.
However, to be more precise, we performed haplotyping of three recurrent LGRs: BRCA1 del(ex17),
BRCA1 del(ex21-22), and BRCA1 dup(ex13). Our results confirmed the common origin of the respective
LGR types possessing the same breakpoint positions. Collaborative haplotyping of BRCA1 dup(ex13)
samples (referred as ins6kbEx13 in publications) collected from geographically diverse populations was
formerly reported by The BRCA1 Exon 13 Duplication Screening Group [42] as a founder mutation with
common origin. Exact sizes of three core STRs of these samples were described by other groups [43,44],
which coincided with our results, therefore our samples turned to be identical with the reported
ones. Similarly, all but one BRCA1 del(ex21-22) samples shared the same haplotype as reported by
Vasickova et al. (2007) [25]. Core haplotype of our four BRCA1 del(ex17) samples were also identical,
but implicitly was not the same as the recurrent German BRCA1 del(ex17) samples with different
intronic breakpoints haplotyped by Engert et al. (2008) [27].
Transcript-level testing of five deletion types yielded the lack of the respective exons at canonical
cassette exon borders on cDNA-level in each case. This indicates that the donor and acceptor sites of
the flanking exons were unaffected, irrespective of the size and position of the missing neighboring
intron stretches, and no alternative splicing anomalies were detected. This provides inference that the
missing intron regions did not contain essential regulation signals for splicing in either case tested.
Benefiting exonic heterozygote BRCA1 markers of the samples we experienced allelic imbalance
of two of the tested four deletion types, BRCA1 del(ex5-10) and BRCA1 del(ex17) at cDNA-level.
This can be attributed to nonsense-mediated mRNA decay (NMD), since BRCA1 mutations resulting
in premature termination codon (PTC) preceding exon-exon junctions normally trigger NMD and
degradation [45]. Indeed, both deletion types harbored PTC. The two other tested deletion types
did not show any sign of allelic imbalance. They comply with the NMD-rule, considering BRCA1
del(ex21-22) is an in-frame deletion without PTC, and BRCA1 del(ex18-22) has its termination codon
in the last coding exon of BRCA1, so these samples evade NMD. Although RNA expression data
arise from peripheral blood rather than tumor tissue samples of the carriers, data are relevant, since
surveys give evidence that BRCA-expression in peripheral blood cells is significantly correlated to
BRCA-mutation carrier status [46].
All LGRs with deletions were ascertained to be clinically significant. In contrast, the pathogenicity
of BRCA1 dup(ex1-2) is still under debate, since it contains an uninterrupted copy of the gene together
with its promoter [7,13]. Similarly, pathogenic nature of the BRCA2 amp(ex21) is also doubtful, because
we failed to characterize breakpoint for tandem sequential amplification.
Since LGRs often span several exons and in some cases also affect neighboring functional genes,
the question emerged if they are associated with more severe pathology. Considering that the great
majority of the LGRs affect the BRCA1 gene it made sense to compare their phenotype data to those
of the non-LGR BRCA1 mutation carriers. Comparison of several pathological features did not yield
a significant difference in any case. Our results confirm that LGRs do not elicit more severe disease than
other, small-scale exonic BRCA1 mutations, in line with other studies [6,28,32,47]. Even the families,
where rearrangements affected also the neighboring NBR2 and NBR1 genes did not show differences
in their phenotype features compared to other LGRs’. Nevertheless, it would be interesting to
examine in more cases, if these mutation carriers show any multilocus phenotype, since recent findings
argue that NBR2 is also involved in cancer pathways [48]. There are examples where impairment of
disease-associated neighboring genes also influenced the disease severity [49], so we cannot exclude
that differences might exist when testing on a larger number of samples.
The survey confirms the necessity for genotyping of LGRs in the course of routine genetic testing,
but with caution for the interpretation of the pathology of these types of rearrangements.
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4. Materials and Methods
4.1. Patient Selection and Genotyping
Breast and ovarian cancer patients were enrolled for germline BRCA1/2 genotyping as part of
the routine genetic counseling in the Department of Molecular Genetics of the National Institute of
Oncology, Budapest, Hungary. Eligibility criteria were positive family history for either breast or
ovarian cancer along with personal clinicopathological features according to the relevant National
Comprehensive Cancer Network (NCCN) guideline versions. Research projects and study protocols
were approved by the Institutional Ethical Board and the Research and Ethics Committee of the
Hungarian Health Science Council (ETT-TUKEB 53720-7/2019/EÜIG, 20 July 2019). All participants
provided written informed consent for the genetic testing.
Genomic DNA was isolated from peripheral white blood cells using the Gentra Puregene Kit
(Qiagen, Hilden, Germany). The probands were either sequenced by conventional Sanger method
on ABI 3130 Genetic Analyzer (Thermo Fisher Scientific, MA, USA) or genotyped by NGS. Sanger
sequencing restricted to the exons and exon-intron boundaries of BRCA1 and BRCA2 genes. Genotyping
by NGS was carried out on Illumina MiSeq platform (Illumina, CA, USA) after an amplicon-based
enrichment library preparation of the BRCA1/2 exons by Multiplicom BRCA MASTR Dx or BRCA
MASTR Plus Dx kit (Agilent Technologies, CA, USA). Library preparation was done according to the
manufacturer’s instructions and pooled libraries from 24 or 48 indexed patients were run on V2-500
sequencing cartridge system (Illumina). Data analysis form FASTQ files to variant calling was done
with Multiplicom MASTR Reporter software (Agilent Technologies) as well as using our in-house
bioinformatics workflow.
4.2. Gene Dosage Analysis
Detection of whole exon deletions or duplications were performed by MLPA method
(MRC-Holland, the Netherlands) with the following probe sets: P002 and P239 for BRCA1, P045 for
BRCA2. To exclude false positive MLPA signals, deletions affecting single exons were reinforced by
confirmation probe set (P087 for BRCA1 and P077 for BRCA2) or sequenced to search for possible
heterozygote variants inside the probe hybridization positions. Samples genotyped by high-coverage
NGS (average read depth exceeding 1000 reads per position) were analyzed for copy number variations
by the CNV analysis algorithm of the Multiplicom MASTR Reporter software (Agilent Technologies)
based on the relative normalized ratio of the aligned read numbers of each amplicon. All suspected
deletions or duplications emerged through this software analysis were confirmed by MLPA.
4.3. Breakpoint Resolution of the LGRs
Primers for long-range PCRs for the respective LGRs were either designed in-house or adapted
from publications (Table S1). PCR reactions were done using Herculase II Fusion DNA Polymerase
(Agilent Technologies, CA, USA). Amplification products were visualized on 1% agarose gels next to
Hyper Ladder 1kb DNA sizing standard (Bioline, London, UK). PCR products containing the deletion
or duplication breakpoints (that is, the junction fragments) were sequenced by conventional Sanger
sequencing method on ABI3130 Genetic Analyzer (Thermo Fisher Scientific) using a series of nested
walking primers to span the breakpoint. Sequencing primers are also listed in Table S1. Exact designation
of the LGR breakpoints was according to the current HGVS nomenclature recommendations [50].
Reference sequence LRG_292t1, which corresponds to NM_007294.3, was used for LGRs inside the
BRCA1 transcript and NG_005905.2 was used for LGRs extending beyond the boundaries of the
BRCA1 transcript towards upstream direction. Reference sequence LRG_293t1, which corresponds
to NM_000059.3, was used for LGRs inside the BRCA2 transcript. The detected LGR variants were
uploaded to the LOVD v.3 Locus Specific Database [51] with accession numbers #296865-#296952.
Primer pairs for QMPSF were designed using the Primer3Plus software (primer sequences are
available in Table S1). One of the PCR primers was labeled with FAM fluorophore and each amplicon
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size was different. PCR reactions were performed by Qiagen Multiplex PCR Kit (Qiagen) with all
primer pairs in one reaction tube. Fluorescent fragment analysis was done on ABI3130 Genetic
Analyzer (Thermo Fisher Scientific) in microsatellite analysis method and the peaks were visualized by
Peak Scanner Software 2.0 provided for the instrument. Height of each peak was compared to the
respective peaks of a control sample after normalization. Amplicons for real time semi-quantitative PCR
(qPCR) tests were designed individually for the interrogated regions (Table S1). PCR reactions were set
according to the instructions of the Brilliant HRM Ultra-Fast Loci Master Mix (Agilent Technologies) and
run on AriaMX Real-time PCR System (Agilent Technologies) detecting FAM fluorescence in real time
over 40 cycles. Two wild-type calibrator samples were run in each experiment. Amplicons designed for
known one-copy regions and known two-copy regions were added as positive and negative controls,
respectively. Results were analyzed by AriaMX Software provided for the instrument. Test regions
with amplicons of ∆∆ Ct number equal 1 were regarded to be deleted in one copy. Individual PCR
reactions were in triplicate and each test was confirmed in an independent reaction.
4.4. Haplotyping
Large genomic rearrangements, which affected the same exon(s) were subjected to haplotype
analysis to reveal their possible common genetic origin. BRCA1 haplotyping was done with short
tandem repeat (STR) polymorphic microsatellite markers locating within the BRCA1 gene and 50 kb
surroundings: D17S1185, D17S1320, D17S1321, D17S855, D17S1322, D17S1323, D17S1327, D17S1326,
D17S1325. PCR primer sequences were taken from https://www.ncbi.nlm.nih.gov/probe. PCR product
fragments were detected on ABI3130 Genetic Analyzer in microsatellite analysis mode. GeneScan
Liz500(-250) (Thermo Fisher Scientific) was used as sizing reference. Peaks were visualized using the
Peak Scanner Software 2.0 and exact marker sizes were assigned for both alleles. Core haplotypes were
determined in each case. Where it was applicable, additional information of other BRCA1 variant
genotypes, originating from the complete sequencing of the coding exons, was also incorporated in the
whole genotype data of a sample and were taken advantage of for haplotyping.
4.5. RNA Isolation and RT-PCR
RNA was isolated by two different techniques: one applied the Tempus Spin RNA Isolation
Kit (Thermo Fisher Scientific) from 9 mL peripheral blood taken into Tempus Blood RNA Tubes
(Thermo Fisher Scientific) according to manufacturer’s instructions. For some samples, RNA was
isolated using the NucleoSpin RNA Plus Kit (Macherey Nagel, Dueren, Germany) from peripheral
blood mononuclear cells stored in RNALater (Sigma-Aldrich, Merck, Darmstadt, Germany), complying
with the manufacturer’s recommendations. RNA quantity and quality were determined by NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific), and 100–200 ng RNA
was converted into cDNA by SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific) using
either random hexamers or oligo dT primers.
4.6. Allele Imbalance
Relative expressions of the variant and wild type BRCA1 alleles were tested by measuring the
Sanger sequencing electropherogram ratio of exonic heterozygote positions. Informative nucleotide
positions were sequenced bi-directionally with flanking exonic primers on cDNA template. Analyzed
sequencing data was visualized in Sequence Scanner program 2.0 (Thermo Fisher Scientific). Peak ratios
for the heterozygote positions were compared to the peak ratios of gDNA sequence of the same position
for the same sample. The relative ratios were calculated, and allelic imbalance was asserted if the
difference was >50%. Information from several heterozygote positions were integrated, where it
was applicable.
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4.7. Statistical Analyses
Statistical analyses of phenotype parameters depending on the type of the data were performed
either by two-tailed t-tests or Fisher’s exact tests. Numerical parameters, such as age at disease onset
and Ki-67 status were compared by two-tailed t-tests. Categorical parameters, such as estrogen and
progesterone receptor, Her2 IHC-status, presence of second primary tumor in the proband and positive
family history were compared by Fisher’s exact tests. Difference was regarded at nominal significance
p ≤ 0.05 at each comparison.
Supplementary Materials: Can be found at http://www.mdpi.com/1422-0067/21/13/4650/s1. Figure S1: Detection
of large genomic rearrangements with a representative example of BRCA1 del(ex18-22). Figure S2: Sequence
electropherograms of the junction regions of all novel LGRs. Table S1: Primers used in our study. Table S2:
Complete list of the detected Hungarian LGR families. Table S3: Statistical comparison of the phenotype features
of LGR and non-LGR BRCA1 mutation carrier patients. Table S4: Haplotyping of BRCA1 dup(ex13) samples.
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